Label: GLUCAGEN- glucagon hydrochloride

  • NDC Code(s): 55390-004-01, 55390-004-10
  • Packager: Bedford Laboratories
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: New Drug Application

Drug Label Information

Updated 05/14

If you are a consumer or patient please visit this version.

  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use GlucaGen safely and effectively. See full prescribing information for GlucaGen.
    GlucaGen ®  (glucagon [rDNA origin] for injection)
    Initial U.S. Approval: 1998

    INDICATIONS AND USAGE

    GlucaGen is an antihypoglycemic agent and a gastrointestinal motility inhibitor indicated for:

    Treatment of severe hypoglycemia ( 1.1)
    Use as a diagnostic aid ( 1.2)

    DOSAGE AND ADMINISTRATION

    Treatment of severe hypoglycemia (GlucaGenHypoKit)

    Reconstitute before administration. ( 2.1)
    Inject 1 mL (adults and children, weighing more than 55 lbs (25 kg)) or 0.5 mL (children weighing less than 55 lbs (25 kg)) subcutaneously, intramuscularly, or intravenously. ( 2.1)
    If the weight is not known: Children younger than 6 years should be given 0.5 mL and children 6 years and older should be given 1 mL. ( 2.1)
    Seek emergency assistance immediately after subcutaneous or intramuscular injection of glucagon. Glucagon injection may be repeated while waiting for emergency assistance. ( 2.1)
    Intravenous glucose MUST be administered if the patient fails to respond to glucagon. ( 2.1)
    When the patient responds to treatment, give oral carbohydrates to restore the liver glycogen and prevent recurrence of hypoglycemia. ( 2.1)

    Use as a diagnostic aid (GlucaGen Diagnostic Kit and GlucaGen 10-Pack)

    Reconstitute before administration. ( 2.2)
    The dose ranges from 0.2 mg to 2 mg depending on the diagnostic technique and the route of administration. ( 2.2)
    After the end of the diagnostic procedure, give oral carbohydrates to patients who have been fasting, if this is compatible with the diagnostic procedure applied. ( 2.2)

    DOSAGE FORMS AND STRENGTHS

    Each vial contains 1 mg/mL (1 unit/mL) GlucaGen when reconstituted with Sterile Water for Reconstitution or Sterile Water for Injection, USP. ( 3)

    CONTRAINDICATIONS

    Do not use in patients with known hypersensitivity to glucagon or lactose ( 4)
    Do not use in patients with pheochromocytoma ( 4)
    Do not use in patients with insulinoma ( 4)

    WARNINGS AND PRECAUTIONS

    Administer cautiously to patients suspected of having pheochromocytoma, insulinoma or glucagonoma due to risk of secondary hypoglycemia. Glucagon may release catecholamines from pheochromocytomas and is contraindicated in patients with this condition. ( 5.1, 5.2)
    Allergic reactions may occur and include generalized rash, and in rare cases anaphylactic shock with breathing difficulties, and hypotension. ( 5.3)
    In order for GlucaGen treatment to reverse hypoglycemia, there must be adequate amounts of glycogen stored in the liver. GlucaGen should be used with caution in patients with conditions resulting in low levels of releasable glucose in the liver. ( 5.4)
    Use caution when glucagon is used as a diagnostic aid in diabetic patients because it may cause hyperglycemia. ( 5.4)
    Use with caution in patients with known cardiac disease, as glucagon increases myocardial oxygen demand. ( 5.5)

    ADVERSE REACTIONS

    Adverse reactions seen with GlucaGen are:

    Nausea and vomiting ( 6)
    Temporary increase in blood pressure and pulse may occur after administration. ( 6)

    To report SUSPECTED ADVERSE REACTIONS, contact Novo Nordisk Inc. at 1-800-727-6500 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

    DRUG INTERACTIONS

    Beta-blockers may cause a greater increase in both pulse and blood pressure after administration. ( 7.1)
    Glucagon may lose its ability to raise blood glucose or may produce hypoglycemia when given with indomethacin. ( 7.2)
    Coadministration with an anticholinergic drug is not recommended due to increased gastrointestinal side effects. ( 7.3)
    Glucagon may increase the anticoagulant effect of warfarin. ( 7.4)
    Insulin reacts antagonistically towards glucagon. ( 7.5)

    USE IN SPECIFIC POPULATIONS

    Nursing mothers: unknown whether drug is excreted in human milk, therefore caution should be exercised. ( 8.3)
    Pediatrics: reported safe and effective for treatment of hypoglycemia. Safety and effectiveness for use as a diagnostic aid have not been established. ( 8.4)

    See 17 for PATIENT COUNSELING INFORMATION.

    Revised: 5/2014

    Close
  • FULL PRESCRIBING INFORMATION: CONTENTS*
  • 1 INDICATIONS AND USAGE

    1.1 Treatment of severe hypoglycemia

    GlucaGen is used to treat severe hypoglycemic (low blood sugar) reactions which may occur in patients with diabetes mellitus treated with insulin. Because GlucaGen depletes glycogen stores, the patient should be given supplemental carbohydrates as soon as he/she awakens and is able to swallow, especially children or adolescents. Medical evaluation is recommended for all patients who experience severe hypoglycemia.

    1.2 Use as a diagnostic aid

    GlucaGen is indicated for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract. Glucagon is as effective for this examination as are the anticholinergic drugs. However, the addition of the anticholinergic agent may result in increased side effects. After the end of the diagnostic procedure, give oral carbohydrates to patients who have been fasting, if this is compatible with the diagnostic procedure applied.

    Close
  • 2 DOSAGE AND ADMINISTRATION

    For GlucaGenHypoKit:

    2.1 Treatment of severe hypoglycemia

    1.
    Using the supplied prefilled syringe, carefully insert the needle through the rubber stopper of the vial containing GlucaGen powder and inject all the liquid from the syringe into the vial.
    2.
    Shake the vial gently until the powder is completely dissolved and no particles remain in the fluid. The reconstituted fluid should be clear and of water-like consistency.
    3.
    The reconstituted GlucaGen gives a concentration of approximately 1 mg/mL glucagon.
    4.
    The reconstituted GlucaGen should be used immediately after reconstitution.
    5.
    Inject 1 mL (adults and children, weighing more than 55 lbs (25 kg)) or 0.5 mL (children weighing less than 55 lbs (25 kg)) subcutaneously, intramuscularly, or intravenously. If the weight is not known: children younger than 6 years should be given a 0.5 mL and children 6 years and older should be given 1 mL.
    6.
    Discard any unused portion.
    7.
    Emergency assistance should be sought immediately after subcutaneous or intramuscular injection of glucagon.
    8.
    The glucagon injection may be repeated using a new kit while waiting for emergency assistance.
    9.
    Intravenous glucose MUST be administered if the patient fails to respond to glucagon.
    10.
    When the patient has responded to the treatment, give oral carbohydrates to restore the liver glycogen and prevent recurrence of hypoglycemia.

    For GlucaGen Diagnostic Kit and the GlucaGen 10-pack:

    2.2 Use as a diagnostic aid

    1.
    GlucaGen should be reconstituted with 1 mL of Sterile Water for Reconstitution (if supplied) or 1 mL of Sterile Water for Injection, USP. Using a syringe, withdraw all of the Sterile Water for Reconstitution (if supplied) or 1 mL Sterile Water for Injection, USP and inject into the GlucaGen vial.
    2.
    Shake the vial gently until the powder is completely dissolved and no particles remain in the fluid. The reconstituted fluid should be clear and of water-like consistency.
    3.
    The reconstituted GlucaGen gives a concentration of approximately 1 mg/mL glucagon.
    4.
    The reconstituted GlucaGen should be used immediately after reconstitution.
    5.
    GlucaGen must be administered by medical personnel.
    6.
    Discard any unused portion.
    7.
    Onset of action after an injection will depend on the organ under examination and route of administration [see Pharmacodynamics (12.2)].
    8.
    The usual diagnostic dose for relaxation of the stomach, duodenal bulb, duodenum, and small bowel is 0.2 mg to 0.5 mg given intravenously or 1 mg given intramuscularly; the usual dose to relax the colon is 0.5 mg to 0.75 mg intravenously and 1 mg to 2 mg intramuscularly [see Pharmacodynamics (12.2)].
    9.
    After the end of the diagnostic procedure, give oral carbohydrates to patients who have been fasting, if this is compatible with the diagnostic procedure applied.

    The GlucaGen Diagnostic Kit and the GlucaGen 10-pack presentations are intended only for use by healthcare providers as a diagnostic aid. The GlucaGen Diagnostic Kit and the GlucaGen 10-pack presentations are not intended for use by patients to treat severe hypoglycemia because they are not packaged with a syringe and diluent necessary for rapid preparation and administration during an emergency outside of a healthcare facility.

    Close
  • 3 DOSAGE FORMS AND STRENGTHS

    GlucaGen is supplied in a vial, alone, or accompanied by Sterile Water for Reconstitution (1 mL) also in a vial (10 pack or diagnostic kit). It is also supplied as GlucaGen HypoKit®, a presentation with a disposable prefilled syringe containing 1 mL Sterile Water for Reconstitution. When the glucagon powder is reconstituted with Sterile Water for Reconstitution (if supplied) or with Sterile Water for Injection, USP, it forms a solution of 1 mg/mL (1 unit/mL) glucagon for subcutaneous, intramuscular, or intravenous injection.

    Close
  • 4 CONTRAINDICATIONS

    GlucaGen is contraindicated in patients with:

    Known hypersensitivity to glucagon, lactose or any other constituent in GlucaGen
    Pheochromocytoma [see Warnings and Precautions (5.1)]
    Insulinoma [see Warnings and Precautions (5.2)]
    Close
  • 5 WARNINGS AND PRECAUTIONS

    5.1 Pheochromocytoma

    Glucagon is contraindicated in patients with pheochromocytoma because Glucagon may stimulate the release of catecholamines from the tumor. If the patient develops a dramatic increase in blood pressure, 5 to 10 mg of phentolamine mesylate has been shown to be effective in lowering blood pressure for the short time that control would be needed.

    5.2 Insulinoma and Glucagonoma

    GlucaGen should be administered cautiously to patients suspected of having insulinoma or glucagonoma. In patients with insulinoma, intravenous administration of glucagon may produce an initial increase in blood glucose; however, glucagon administration may directly or indirectly (through an initial rise in blood glucose) stimulate exaggerated insulin release from an insulinoma. A patient developing symptoms of hypoglycemia after a dose of glucagon should be given glucose orally or intravenously, whichever is most appropriate. Caution should also be observed in administering GlucaGen to patients with glucagonoma.

    5.3 Hypersensitivity and Allergic Reactions

    Allergic reactions may occur and include generalized rash, and in some cases anaphylactic shock with breathing difficulties, and hypotension. The anaphylactic reactions have generally occurred in association with endoscopic examination during which patients often received other agents including contrast media and local anesthetics. The patients should be given standard treatment for anaphylaxis including an injection of epinephrine if they encounter respiratory difficulties after GlucaGen injection.

    5.4 Glycogen Stores and Hypoglycemia

    In order for GlucaGen treatment to reverse hypoglycemia, adequate amounts of glucose must be stored in the liver (as glycogen). Therefore, GlucaGen should be used with caution in patients with conditions such as prolonged fasting, starvation, adrenal insufficiency or chronic hypoglycemia because these conditions result in low levels of releasable glucose in the liver and an inadequate reversal of hypoglycemia by GlucaGen treatment.

    5.5 Cardiac Disease

    Caution should be observed when glucagon is used as an adjunct in endoscopic or radiographic procedures to inhibit gastrointestinal motility in patients with known cardiac disease.

    5.6 Laboratory Tests

    Blood glucose measurements may be considered to monitor the patient’s response.

    Close
  • 6 ADVERSE REACTIONS

    Side effects may include nausea and vomiting at doses above 1 mg or with rapid injection. Hypotension has been reported up to 2 hours after administration in patients receiving GlucaGen as premedication for upper GI endoscopy procedures. Glucagon exerts positive inotropic and chronotropic effects and may, therefore, cause tachycardia and hypertension. Adverse reactions indicating toxicity of GlucaGen have not been reported. A temporary increase in both blood pressure and pulse rate may occur following the administration of glucagon. Patients taking beta-blockers might be expected to have a greater increase in both pulse and blood pressure, an increase of which will be temporary because of glucagon’s short half-life [see Drug Interactions (7.1)]. The increase in blood pressure and pulse rate may require therapy in patients with pheochromocytoma or coronary artery disease [see Warnings and Precautions (5.1)]. Anaphylactic reactions may occur in some cases [see Warnings and Precautions (5.3)].

    The following adverse reactions have been identified during postapproval use of GlucaGen. Because these adverse reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency.

    Table 1 Frequency of Adverse Reactions

    Treatment of severe hypoglycemia

    Frequency (%)

    Adverse Reaction

    < 10

    Nausea

    < 1

    Vomiting

    Use as a diagnostic aid

    < 10

    Nausea

    < 1

    Vomiting

    < 1

    Hypoglycemia

    <1

    Hypoglycemic coma

    Close
  • 7 DRUG INTERACTIONS

    7.1 Beta-blockers

    Patients taking beta-blockers might be expected to have a greater increase in both pulse and blood pressure, an increase of which will be temporary because of glucagon’s short half-life. The increase in blood pressure and pulse rate may require therapy in patients with pheochromocytoma or coronary artery disease.

    7.2 Indomethacin

    When used with indomethacin, glucagon may lose its ability to raise blood glucose or may even produce hypoglycemia. Therefore, caution should be exercised for patients taking indomethacin when glucagon will be administered.

    7.3 Anticholinergic Drugs

    Coadministration with an anticholinergic drug is not recommended due to increased gastrointestinal side effects.

    7.4 Warfarin

    Glucagon may increase the anticoagulant effect of warfarin. Therefore, caution should be exercised for patients taking warfarin when glucagon will be administered.

    7.5 Insulin

    Insulin reacts antagonistically towards glucagon. Therefore, caution should be exercised when glucagon is used as a diagnostic aid in diabetes patients.

    Close
  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Pregnancy Category B. Reproduction studies were performed in rats and rabbits at GlucaGen doses of 0.4, 2.0, and 10 mg/kg. These doses represent exposures of up to 100 and 200 times the human dose based on mg/m2 for rats and rabbits, respectively, and revealed no evidence of harm to the fetus. There are, however, no adequate and well-controlled studies in pregnant women. Glucagon does not cross the human placenta barrier.

    8.3 Nursing Mothers

    It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when GlucaGen is administered to a nursing woman. No clinical studies have been performed in nursing mothers, however, GlucaGen is a peptide and intact glucagon is not absorbed from the GI tract. Therefore, even if the infant ingested glucagon it would be unlikely to have any effect on the infant. Additionally, GlucaGen has a short plasma half-life thus limiting amounts available to the child. Glucagon does not cross the human placental barrier.

    8.4 Pediatric Use

    For the treatment of severe hypoglycemia: The use of glucagon in pediatric patients has been reported to be safe and effective.

    For use as a diagnostic aid: Safety and effectiveness in pediatric patients have not been established.

    Close
  • 10 OVERDOSAGE

    No reports of overdosage with GlucaGen have been reported. If overdosage occurs, the patient may experience nausea, vomiting, inhibition of GI tract motility, increase in blood pressure and pulse rate. In case of suspected overdosing, the serum potassium may decrease and should be monitored and corrected if needed. If the patient develops a dramatic increase in blood pressure, phentolamine mesylate has been shown to be effective in lowering blood pressure for the short time that control would be needed.

    Close
  • 11 DESCRIPTION

    GlucaGen (glucagon [rDNA origin] for injection) is an antihypoglycemic agent and a gastrointestinal motility inhibitor. It is produced by expression of recombinant DNA in a Saccharomyces cerevisiae vector with subsequent purification. The chemical structure of the glucagon in GlucaGen is identical to human glucagon and to glucagon extracted from beef and pork pancreas. Glucagon with the empirical formula of C153H225N43O49S, and a molecular weight of 3483, is a single-chain polypeptide containing 29 amino acid residues. The structure of glucagon is:

    Structural formula of GlucaGen.

    GlucaGen is a sterile, lyophilized white powder in a 2 mL vial. The reconstituted solution contains glucagon as hydrochloride 1 mg/mL (1 unit/mL) and lactose monohydrate (107 mg). GlucaGen is supplied at pH 2.5-3.5 and is soluble in water.

    Close
  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Antihypoglycemic Action: Glucagon induces liver glycogen breakdown, releasing glucose from the liver. Hepatic stores of glycogen are necessary for glucagon to produce an antihypoglycemic effect.

    Gastrointestinal Motility Inhibition: Extra hepatic effects of glucagon include relaxation of the smooth muscle of the stomach, duodenum, small bowel, and colon.

    12.2 Pharmacodynamics

    For the treatment of severe hypoglycemia:

    Blood glucose concentration rises within 10 minutes of injection and maximal concentrations are attained at approximately 30 minutes after injection (see Figure 1). The duration of hyperglycemic action after intravenous or intramuscular injection is 60 – 90 minutes.

    Graph

    Figure 1. Recovery from Insulin Induced Hypoglycemia (mean blood glucose) After Intramuscular Injection of 1 mg GlucaGen in Type I Diabetic Men

    For use as a diagnostic aid:

    Table 2 Pharmacodynamic Properties of Glucagon
    *
    The usual diagnostic dose for relaxation of the stomach, duodenal bulb, duodenum, and small bowel is 0.2 – 0.5 mg given intravenously or 1 mg given intramuscularly; the usual dose to relax the colon is 0.5 – 0.75 mg intravenously and 1 – 2 mg intramuscularly.
    Note: The time of maximal glucose concentration for GlucaGen administered subcutaneously is 30-45 minutes.

    Route of Administration

    Dose*

    Time of Maximal Glucose Concentration

    Time of Onset of Action for GI Smooth Muscle Relaxation

    Duration of Smooth Muscle Relaxation

    IV

    0.25-0.5 mg (0.25-0.5 units)

    5-20 minutes

    45 seconds

    9-17 minutes

    2 mg (2 units)

    5-20 minutes

    45 seconds

    22-25 minutes

    IM

    1 mg (1 unit)

    30 minutes

    8-10 minutes

    12-27 minutes

    2 mg (2 units)

    30 minutes

    4-7 minutes

    21-32 minutes

    12.3 Pharmacokinetics

    Intramuscular injection of 1 mg GlucaGen resulted in a mean Cmax (CV%) of 1686 pg/mL (43%) and median Tmax of 12.5 minutes. The mean apparent half-life of 45 minutes after intramuscular injection probably reflects prolonged absorption from the injection site. Glucagon is degraded in the liver, kidney, and plasma. 

    Close
  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Long term studies in animals to evaluate carcinogenic potential have not been performed. Several studies have been conducted to evaluate the mutagenic potential of glucagon. The mutagenic potential tested in the Ames and human lymphocyte assays, was borderline positive under certain conditions for both glucagon (pancreatic) and glucagon (rDNA) origin. In vivo, very high doses (100 and 200 mg/kg) of glucagon (both origins) gave a slightly higher incidence of micronucleus formation in male mice but there was no effect in females. The weight of evidence indicates that GlucaGen is not different from glucagon pancreatic origin and does not pose a genotoxic risk to humans. GlucaGen (rDNA origin) was not tested in animal fertility studies. Studies in rats have shown that pancreatic glucagon does not cause impaired fertility. 

    Close
  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    16.1 How Supplied

    GlucaGen is supplied as a sterile, lyophilized white powder in a vial, alone, or accompanied by Sterile Water for Reconstitution also in a vial (Diagnostic Kit or 10-pack). It is also supplied as GlucaGen HypoKit with a disposable prefilled syringe containing Sterile Water for Reconstitution.

    GlucaGenHypoKit includes:

    1 vial containing 1 mg (1 unit) GlucaGen (glucagon [rDNA origin] for injection)

    1 disposable syringe containing 1 mL Sterile Water for Reconstitution

    NDC 0169-7065-15

    GlucaGen Diagnostic Kit includes:

    1 vial containing 1 mg (1 unit) GlucaGen (glucagon [rDNA origin] for injection)

    1 vial containing 1 mL Sterile Water for Reconstitution

    NDC 55390-004-01

    GlucaGenHypoKit (Two-Pack) includes: 2 packs of GlucaGen HypoKit,

    Each HypoKit contains:

    1 vial containing 1 mg (1 unit) GlucaGen (glucagon [rDNA origin] for injection)

    1 disposable syringe containing 1 mL Sterile Water for Reconstitution

    NDC 0169-7065-21

    The GlucaGen 10-pack includes:

    10 vials, each containing 1 mg (1 unit) GlucaGen (glucagon [rDNA origin] for injection)

    NDC 55390-004-10

    16.2 Recommended Storage

    Before Reconstitution:

    The GlucaGen package may be stored up to 24 months at controlled room temperature 20o to 25o C (68o to 77o F) prior to reconstitution. Do not freeze. Keep in the original package to protect from light. GlucaGen should not be used after the expiry date on the vials.

    After Reconstitution:

    Reconstituted GlucaGen should be used immediately. Discard any unused portion. If the solution shows any sign of gel formation or particles, it should be discarded.

    Close
  • 17 PATIENT COUNSELING INFORMATION

     [See FDA-Approved Patient Labeling (Patient Instructions for Emergency Use).]

    17.1 Physician Instructions

    Refer patients and family members to the FDA-approved patient labeling for instructions describing the method of preparing and injecting GlucaGen. Advise the patient and family members to become familiar with the technique of preparing glucagon before an emergency arises. Instruct patients to use 1 mg for adults or ½ the adult dose (0.5 mg) for children weighing less than 55 lb (25 kg). To prevent severe hypoglycemia, patients and family members should be informed of the symptoms of mild hypoglycemia and how to treat it appropriately. Family members should be informed to arouse the patient as quickly as possible because prolonged hypoglycemia may result in damage to the central nervous system. Patients should be advised to inform their physician when hypoglycemic reactions occur so that the treatment regimen may be adjusted if necessary.

    No studies on the effects on the ability to drive and use machines have been performed. After diagnostic procedures, hypoglycemia has been reported infrequently. The patient’s ability to concentrate and react may be impaired as a result of hypoglycemia. This may present a risk in situations where these abilities are especially important, such as driving or operating machinery. Therefore, these activities should be avoided until the patient has had a meal with oral carbohydrates.

    Date of issue: May, 2014

    Version: 5

    GlucaGen® and HypoKit® are registered trademarks of Novo Nordisk A/S

    © 1998-2014 Novo Nordisk

    For information contact:

    Bedford Laboratories

    Bedford, OH 44146

    1-800-521-5169

    www.bedfordlabs.com

    Manufactured for:

    Bedford Laboratories

    Bedford, OH 44146

    By:

    Novo Nordisk A/S

    2880 Bagsvaerd, Denmark

    Close
  • PRINCIPAL DISPLAY PANEL - GlucaGen diagnostic kit

    NDC 55390-004-01

    GlucaGen®

    [glucagon (rDNA origin) for injection]

    1 mg per vial

    For intramuscular or intravenous injection

    GlucaGen® should be reconstituted
    with Sterile Water for Reconstitution
    immediately before use

    Single use only. Discard unused portion.

    Protect from Light.

    See package insert for complete product
    information.

    FOR DIAGNOSTIC USE ONLY - NOT INTENDED FOR
    USE BY PATIENTS TO TREAT SEVERE
    HYPOGLYCEMIA

    Rx ONLY

    BEDFORD
    Laboratories

    1 mg Carton
    Close
  • PRINCIPAL DISPLAY PANEL - GlucaGen diagnostic kit - (10 Pack)

    NDC 55390-004-10

    10 vials each containing 1 mg per vial

    GlucaGen®

    [glucagon (rDNA origin) for injection]

    1 mg per vial

    For intramuscular or intravenous injection

    Protect from Light

    FOR DIAGNOSTIC USE ONLY - NOT INTENDED FOR
    USE BY PATIENTS TO TREAT SEVERE HYPOGLYCEMIA

    Rx ONLY

    BEDFORD
    Laboratories

    10 x 1 mg Carton
    Close
  • INGREDIENTS AND APPEARANCE
    GLUCAGEN 
    glucagon hydrochloride kit
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:55390-004
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:55390-004-01 1 in 1 KIT
    2 NDC:55390-004-10 10 in 1 CARTON
    2 1 in 1 KIT
    Quantity of Parts
    Part # Package Quantity Total Product Quantity
    Part 1 1 VIAL, GLASS 1 mL
    Part 2 1 VIAL, GLASS 1 mL
    Part 1 of 2
    GLUCAGEN 
    glucagon hydrochloride injection, powder, for solution
    Product Information
    Route of Administration INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    GLUCAGON HYDROCHLORIDE (glucagon) glucagon 1 mg  in 1 mL
    Inactive Ingredients
    Ingredient Name Strength
    LACTOSE MONOHYDRATE 107 mg  in 1 mL
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 1 mL in 1 VIAL, GLASS
    2 10 in 1 CARTON
    2 1 mL in 1 VIAL, GLASS
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA020918 06/22/2005
    Part 2 of 2
    WATER 
    water liquid
    Product Information
    Route of Administration INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS DEA Schedule     
    Inactive Ingredients
    Ingredient Name Strength
    WATER 1 mL  in 1 mL
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 1 mL in 1 VIAL, GLASS
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA020918 06/22/2005
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA020918 06/22/2005
    Labeler - Bedford Laboratories (884528407)
    Registrant - Novo Nordisk (622920320)
    Establishment
    Name Address ID/FEI Business Operations
    Novo Nordisk A/S 306711800 MANUFACTURE(55390-004)
    Close